Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs
The drugs of programmed cell death 1 and its ligand 1 immune checkpoint inhibitors have ushered in a new era of anti-tumor immunotherapy, which has shown outstanding efficacy in some tumors, such as Hodgkin lymphoma, but there is still low response rate in some kinds of tumors. In recent years, bispecific antibodies prepared by cell fusion, recombinant DNA, protein engineering and other technologies can specifically bind two antigens or epitopes at the same time or successively, play a synergistic role in tumor treatment, can effectively inhibit tumor immune escape, and improve the effect of anti-tumor treatment has become a hot spot in tumor research. This paper will summarize the clinical research and development of bispecific antibodies, to provide reference for the industry.
.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Zhongguo fei ai za zhi = Chinese journal of lung cancer - 25(2022), 9 vom: 20. Sept., Seite 684-688 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Song, Yuanyuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Bispecific |
|---|
| Anmerkungen: |
Date Completed 30.09.2022 Date Revised 25.10.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3779/j.issn.1009-3419.2022.101.43 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346882923 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346882923 | ||
| 003 | DE-627 | ||
| 005 | 20231226032519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3779/j.issn.1009-3419.2022.101.43 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM346882923 | ||
| 035 | |a (NLM)36172734 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Song, Yuanyuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.09.2022 | ||
| 500 | |a Date Revised 25.10.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The drugs of programmed cell death 1 and its ligand 1 immune checkpoint inhibitors have ushered in a new era of anti-tumor immunotherapy, which has shown outstanding efficacy in some tumors, such as Hodgkin lymphoma, but there is still low response rate in some kinds of tumors. In recent years, bispecific antibodies prepared by cell fusion, recombinant DNA, protein engineering and other technologies can specifically bind two antigens or epitopes at the same time or successively, play a synergistic role in tumor treatment, can effectively inhibit tumor immune escape, and improve the effect of anti-tumor treatment has become a hot spot in tumor research. This paper will summarize the clinical research and development of bispecific antibodies, to provide reference for the industry. | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bispecific antibody | |
| 650 | 4 | |a Clinical research | |
| 650 | 4 | |a Research progress | |
| 650 | 7 | |a Antibodies, Bispecific |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a DNA, Recombinant |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 700 | 1 | |a Tang, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zhimin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhongguo fei ai za zhi = Chinese journal of lung cancer |d 1998 |g 25(2022), 9 vom: 20. Sept., Seite 684-688 |w (DE-627)NLM199966222 |x 1999-6187 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2022 |g number:9 |g day:20 |g month:09 |g pages:684-688 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.43 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2022 |e 9 |b 20 |c 09 |h 684-688 | ||